Drug distributor AmerisourceBergen’s business consulting unit Xcenda has written an issue brief for drug industry-led group AIR340B saying Congress and the executive branch should revise 340B eligibility standards to keep 340B “from being used solely as a profit center for hospitals and pharmacies that do not serve low-income and underserved patients in the communities where they live.”
The paper found that 38% of 340B disproportionate share (DSH) hospitals, 29% percent of their child sites, and 26% of their contract pharmacies are in medically underserved areas (MUAs)—places designated by the U.S. Health Resources and Services Administration (HRSA) as having too few primary care providers, high infant mortality, high poverty, or a high elderly population.
Drug distributor AmerisourceBergen’s business consulting unit Xcenda has written an issue brief for drug industry-led group AIR340B saying Congress and the executive branch should revise 340B eligibility standards to keep 340B “from being used solely as a profit center for hospitals and pharmacies that do not serve low-income and underserved patients in the communities where they live.”
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
